Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of TRC101 in Subjects With Metabolic Acidosis Associated With Chronic Kidney Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Blood bicarbonate level of 12 to 20 mEq/L.~* Estimated glomerular filtration rate (eGFR) of 20 to 40 mL/min/1.73m2.~* Stable kidney function defined as \<=20% variability in eGFR during screening period.~Key Exclusion Criteria:~* Any level of low blood bicarbonate during the screening period that in the opinion of the Investigator, requires emergency intervention or evaluation for an acute acidotic process.~* Anuria, dialysis, acute kidney injury, or history of acute kidney insufficiency within 3 months prior to screening.~* Heart failure with maximum New York Heart Association (NYHA) Class IV symptoms or that required hospitalization during the preceding 6 months.~* Heart or kidney transplant.~* Chronic obstructive pulmonary disease (COPD) that is treated with chronic oral steroids, that requires the subject to be on oxygen, or that required hospitalization within the previous 6 months.~* Change in doses to alkali therapy in the 4 weeks prior to screening.~* History or current diagnosis of diabetic gastroparesis, bowel obstruction, swallowing disorders, inflammatory bowel disease, major gastrointestinal surgery, frequent diarrhea or active gastric/duodenal ulcers.~* Serum calcium \<= 8.0 mg/dL at screening.~* Planned initiation of renal replacement therapy within 12 weeks following randomization.~* Use of polymeric binder drugs within 14 days prior to screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- TRC101 (Type: EXPERIMENTAL): Administered once daily (QD) for 12 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Administered once daily (QD) for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).